Novartis Cuts U.S. Cardiovascular Commercial Roles in Entresto Field Force Restructuring
By FieldPulse Editorial · February 20, 2026
Tags: layoffs, restructuring, cardiovascular
Novartis is restructuring its U.S. cardiovascular commercial organization, consolidating the Entresto and Leqvio field forces ahead of the Entresto patent cliff.
Novartis has been restructuring its U.S.
cardiovascular commercial organization, with WARN notices filed for hundreds of field positions as the company consolidates its Entresto and Leqvio sales forces ahead of the Entresto patent expiration.
The restructuring reflects a broader strategic pivot in Novartis cardiovascular, where Entresto faces generic competition and Leqvio (inclisiran) has faced slower-than-expected market adoption.
The company has said it is redeploying resources toward higher-growth pipeline assets in oncology and immunology.
For reps currently in the Entresto and Leqvio organizations, the restructuring has meant territory consolidations, layoffs, and in some cases absorbing significantly larger account lists with reduced support infrastructure.
Leadership has emphasized retraining and internal mobility programs for affected employees, though field reception to those programs has been mixed.